Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial
Fundación Agencia Aragonesa para la Investigación y el Desarrollo
Medical Research Council
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial
Martin Kappler, Andriy Krendyukov, Julián Pardo, Felix Herth et al.
Citations
3 citations
Journal
EClinicalMedicine
Topics
Phagocytosis and Immune Regulation
Field-Weighted Citation Impact (FWCI)
0.72
article
Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial
Martin Kappler, Andriy Krendyukov, Julián Pardo, Felix Herth, Harald Fricke, Christiane Dings, Michael Bergmann, Christian Schoergenhofer, Christine Straub, Thorsten Lehr, Bernd Jilma, Henning Walczak, Diego de Miguel, Meinolf Thiemann, M Seco, José Ramón Paño Pardo, Thomas Hoeger
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 77
Institutions
University of Cologne (DE), Universidad de Zaragoza (ES), Instituto de Salud Carlos III (ES), Apogenix (Germany) (DE), Comprehensive Cancer Center Vienna (AT), Hautklinik Heidelberg (DE), Frauenklinik Heidelberg (DE), Hospital Clínico Universitario Lozano Blesa (ES), Instituto de Investigación Sanitaria Aragón (ES), CRUK Lung Cancer Centre of Excellence (GB), Hospital Universitario Infanta Sofía (ES), Instituto de Investigación de Enfermedades Raras (ES), University College London (GB), Medical University of Vienna (AT), Saarland University (DE), Cytel (United States) (US)
Funders
Alexander von Humboldt-Stiftung, Wellcome Trust, Ministerio de Ciencia, Innovación y Universidades, Deutsche Forschungsgemeinschaft, Vienna Science and Technology Fund, Fundación Agencia Aragonesa para la Investigación y el Desarrollo, Medical Research Council